Tiger Brokers

Market Chatter: Eli Lilly in Talks to Acquire AtaiBeckley

MT Newswires Live
Jul 16

Eli Lilly (LLY) is in talks to acquire psychedelic drug developer AtaiBeckley (ATAI) in a deal that could be announced as soon as this week, Bloomberg reported late Wednesday, citing people familiar with the matter.

Eli Lilly is negotiating to acquire the company at a premium to its market value, according to the report, citing the people.

AtaiBeckley was reportedly exploring options for its lead depression treatment, BPL-003, and a transaction would expand Eli Lilly's neuroscience portfolio, Bloomberg said.

Eli Lilly did not immediately respond to MT Newswires' request for comment.

AtaiBeckley shares were 63% higher in Thursday premarket activity.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10